TASK-5 inhibitors are a class of chemical compounds designed to target and inhibit the activity of TASK-5, a member of the two-pore domain potassium (K2P) channel family. TASK-5, like other K2P channels, is involved in maintaining the resting membrane potential of cells by allowing potassium ions to flow across the cell membrane. These channels help regulate the excitability of cells, particularly in tissues like the nervous system, where ion gradients are crucial for controlling the electrical activity of neurons. TASK-5 is less understood compared to other members of the K2P family, but it is believed to contribute to the fine-tuning of membrane potential and cellular responses to changes in extracellular conditions such as pH, oxygen levels, and mechanical stretch. By inhibiting TASK-5, these compounds block potassium ion flow through the channel, altering the membrane potential and impacting cellular excitability.
Studying TASK-5 inhibitors provides important insights into the physiological role of this specific potassium channel and its contribution to ion homeostasis in different tissues. Researchers can use these inhibitors to explore how TASK-5 influences the resting membrane potential and how its inhibition affects cellular excitability and signaling. Since TASK-5 channels are believed to respond to environmental changes, inhibition of TASK-5 allows scientists to investigate the channel's role in cellular adaptation to stressors such as pH changes or mechanical forces. Additionally, TASK-5 inhibitors help unravel the broader mechanisms by which K2P channels regulate ion flow and contribute to the overall electrical properties of cells, particularly in excitable tissues like neurons and muscle cells. These inhibitors serve as valuable tools for studying potassium channel dynamics and their role in maintaining cellular function and stability in various biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide may inhibit transcription factors, resulting in decreased KCNK15 mRNA synthesis. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D binds to DNA and prevents mRNA synthesis, reducing KCNK15 expression. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin inhibits RNA polymerase II, thereby reducing KCNK15 mRNA transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can downregulate protein translation, affecting KCNK15 expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine incorporates into RNA, destabilizing it and potentially reducing KCNK15 mRNA levels. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB inhibits RNA polymerase II, decreasing KCNK15 mRNA transcription. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A binds to GC-rich DNA sequences, inhibiting transcription of genes like KCNK15. | ||||||
Cordycepin | 73-03-0 | sc-203902 | 10 mg | $101.00 | 5 | |
Cordycepin terminates mRNA elongation, potentially reducing KCNK15 mRNA stability. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin inhibits PI3K and other kinases, which may downregulate KCNK15 expression. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 inhibits proteasomes, leading to reduced transcription factor availability for KCNK15 gene. | ||||||